Model Medicines is an AI-native biotechnology company developing first-in-class small-molecule therapeutics by targeting conserved biological choke points that drive disease across multiple indications. Its proprietary discovery platform integrates multimodal AI, generative chemistry, and predictive safety modeling to enable end-to-end drug discovery, from novel target identification through preclinical proof-of-concept. The lead program, MDL-001, is the first oral, direct-acting, non-nucleoside antiviral targeting a previously undiscovered allosteric site in viral RNA-dependent RNA polymerase (RdRp Thumb-1). MDL-001 has demonstrated broad-spectrum preclinical efficacy across respiratory and liver viruses, including SARS-CoV-2, influenza, RSV, HCV, HBV, and HDV, and is advancing toward IND submission in late 2026. MDL-001 was presented at IDWeek, The Liver Meeting® (AASLD), and HepDART. Model Medicines was recently named a Fierce 15 company and selected for BARDA’s VANGUARD program.